{
    "nctId": "NCT03507088",
    "briefTitle": "Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer",
    "officialTitle": "Fluorine-18 Fluoroestradiol Positron Emission Tomography-computed Tomography: an in Vivo Biomarker Predicting Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer?",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 36,
    "primaryOutcomeMeasure": "To evaluate the accuracy of the change of FES uptake in predicting progression-free survival(PFS) in patients treated with fulvestrant 500 mg",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with a history of histological proven ER-positive primary breast cancer and, whenever available, histological proven ER-positive recurrence.\n2. No previous fulvestrant treatment\n3. ER-antagonists should be discontinued for 5 weeks prior to FES-PET. The use of aromatase inhibitors is allowed.\n4. Age \\> 18\n5. ECOG 0-2\n6. Life expectancy \\> 6 months\n7. Informed consent obtained\n8. Able to comply with the protocol\n\nExclusion Criteria:\n\n1. Presence of life-threatening visceral metastases\n2. Evidence of central nervous system metastases\n3. \\> 3 lines of endocrine therapy for metastatic disease\n4. Isolated liver metastasis (high FES uptake by normal liver)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}